QSAR Modelling to Identify LRRK2 Inhibitors for Parkinson's Disease

J Integr Bioinform. 2019 Feb 14;16(1):20180063. doi: 10.1515/jib-2018-0063.

Abstract

Parkinson's disease is one of the most common neurodegenerative illnesses in older persons and the leucine-rich repeat kinase 2 (LRRK2) is an auspicious target for its pharmacological treatment. In this work, quantitative structure-activity relationship (QSAR) models for identification of putative inhibitors of LRRK2 protein are developed by using an in-house chemical library and several machine learning techniques. The methodology applied in this paper has two steps: first, alternative subsets of molecular descriptors useful for characterizing LRRK2 inhibitors are chosen by a multi-objective feature selection method; secondly, QSAR models are learned by using these subsets and three different strategies for supervised learning. The qualities of all these QSAR models are compared by classical metrics and the best models are discussed in statistical and physicochemical terms.

Keywords: Cheminformatics; LRRK2; Machine Learning; Parkinson’s disease; QSAR.

MeSH terms

  • Computer Simulation
  • Humans
  • Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 / antagonists & inhibitors*
  • Models, Molecular*
  • Molecular Structure
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / enzymology
  • Protein Kinase Inhibitors / chemistry*
  • Protein Kinase Inhibitors / pharmacology*
  • Quantitative Structure-Activity Relationship*

Substances

  • Protein Kinase Inhibitors
  • LRRK2 protein, human
  • Leucine-Rich Repeat Serine-Threonine Protein Kinase-2

Grants and funding

This work is kindly supported by CONICET, Funder Id: 10.13039/501100002923, grant PIP 112-2012-0100471 and UNS, Funder Id: 10.13039/501100007869, grants PGI 24/N042 and PGI 24/ZM17. We also acknowledge MECD, VSP grant FPU15/01465, Funder Id: 10.13039/501100003176 and Banco Santander for Funder Id: 10.13039/100010784, VSP fellowship AY21/17-D-27 in the “Becas Iberoamerica-Santander Investigación” program.